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Dear Home Secretary,
The Advisory Council on the Misuse of Drugs (ACMD) recently considered that a 
review of MDMA (‘ecstasy’) would be timely as there is a much greater body of 
evidence regarding the harms and misuse of MDMA since the Council last provided 
its advice to Ministers in 1996. I have pleasure in enclosing the Council’s report.
The use of MDMA is undoubtedly harmful. I would therefore like to emphasise 
that the Council continues to be concerned about the widespread use of MDMA; 
particularly among young people.
Due to its prevalence of use, MDMA is a significant public health issue and we 
believe that criminal justice measures will only have limited effect. You will wish to 
note that the Council strongly advises the promulgation of public health messages. 
It is of vital importance that issues of classification do not detract from messages 
concerning public health.
Forensic evidence shows that MDMA is by far the most commonly seized of the 
‘ecstasy-like’ drugs. MDMA is presently generically classified in Class A under the 
Misuse of Drugs Act with other ‘ecstasy-like’ drugs. The ACMD has not extended 
this review to other compounds within the generic classification since their use is 
considerably less than that of MDMA.
In reviewing the evidence of the harmfulness of MDMA to individuals and society, 
the Council’s collective view is that the balance of harms most closely equates to 
that of other substances in Class B.
Despite the current generic definition of ‘ecstasy-like’ drugs, it is not envisaged 
that the Council’s recommendation concerning the classification of MDMA and 
subsequent changes to the legislation would be difficult to enact. For example, in 
New Zealand, MDMA was previously generically classified, but MDMA has recently 
been re-scheduled in a lower classification. This model retains other ‘ecstasy-like’ 
compounds in the higher classification.
The report includes a number of research recommendations. The Council believes 
that the outcomes of research commissioned in these areas will positively 
contribute to the evidence base for the development of specific policies for 
tackling the misuse of MDMA. We applaud the on-going development of the cross-
government drugs research strategy and hope that these recommendations will 
contribute to its development.
The production of this report has been greatly aided by valuable contributions from 
a wide range of organisations and experts. The Council is particularly grateful to 
those experts who provided written and oral evidence.
Yours sincerely,
Professor David nutt fMedsci 
AcMD chairman
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Preamble 
3,4-Methylenedioxymethylamphetamine (MDMA), colloquially known as ‘ecstasy’, is 
a Class A drug, the use of which increases the feeling of euphoria and induces a 
heightened sense of intimacy with others. 
The Advisory Council on the Misuse of Drugs (ACMD) considers that a review of 
MDMA would be timely given: that there is a greater body of scientific evidence 
now available since the ACMD’s last advice to Ministers; the further information 
available on current use; and the length of time since the ACMD last provided 
advice to Ministers.1 Indeed, a recent inquiry by the House of Commons Science 
and Technology Select Committee into the Government’s handling of scientific 
advice, risk and evidence in policy making (House of Commons Science and 
Technology Select Committee, 2006) recommended that the ACMD should use the 
now expanded knowledge base to review the classification of ‘ecstasy’ under the 
Misuse of Drugs Act 1971. This report represents the output of a review of MDMA 
which was conducted by the ACMD during 2008.
1  1996 ACMD advice to Ministers regarding ‘ecstasy’.
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1. Background
1.1 The Advisory Council on the Misuse of Drugs (the Council) is established 
under the Misuse of Drugs Act 1971. The Council’s current membership 
is shown in Annex A. Additional experts also attended the Council’s 
meetings to assist in the preparation of this report (Annex B).
1.2 The Council is required under the Misuse of Drugs Act 1971 “to keep 
under review the situation in the United Kingdom with respect to drugs 
which appear to them likely to be misused and of which the misuse is 
having or appears to them of having effects sufficient to constitute a 
social problem”.
1.3 Substances that are controlled under the Misuse of Drugs Act 1971 are 
grouped into one of three classes in a system of relative-based harms:
 class A (the most harmful) includes cocaine, diamorphine (heroin), 
3,4-methylenedioxymethylamphetamine (‘ecstasy’), lysergic acid 
diethylamide (LSD), and methylamphetamine. 
 class B (intermediate category) includes amphetamine, barbiturates, 
codeine and methylphenidate.
 class c (less harmful) includes benzodiazepines, buprenorphine, anabolic 
steroids, gamma-hydroxybutyrate (GHB) and ketamine.
1.4 As devised, this system of classification, which is based on the 
harmfulness to individuals and society, serves to determine the penalties 
for the possession and supply of controlled substances. The current 
maximum penalties are as follows:
 class A drugs: For possession – 7 years’ imprisonment and/or an 
unlimited fine; for supply – life imprisonment and/or fine.
 class B drugs: For possession – 5 years’ imprisonment and/or an 
unlimited fine; for supply – 14 years’ imprisonment and/or fine.
 class c drugs: For possession – 2 years’ imprisonment and/or an 
unlimited fine; for supply – 14 years’ imprisonment and/or fine.
1.5 In 1977, MDMA and other ring-substituted phenylethylamines were 
generically classified under the Misuse of Drugs Act as Class A 
drugs. Some other countries, at about a similar time, took the 
same generic approach, including the Republic of Ireland and New 
Zealand, whereas others enacted drug-specific rather than generic 
controls. Subsequent amendments to the New Zealand legislature 
have re-classified MDMA within Class B Part 2 of their legislation, 
yet 3,4-methylenedioxyamphetamine (MDA) and 3-methoxy-4,5-
methylenedioxyamphetamine (MMDA) (other drugs considered ‘ecstasy-
like’) have been retained in Class A.  
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1.6 MDMA was given Class A status as at the time it was considered to be 
a hallucinogen like LSD, which had also been placed in Class A when the 
Misuse of Drugs Act was introduced in 1971. Subsequent experience, 
however, showed that MDMA does not usually cause hallucinations (Green 
et al., 2003), although these may sometimes occur as an adverse effect 
(Davison and Parrott, 1998). MDMA has no recognised medicinal use 
and is therefore placed in Schedule 1 of the Misuse of Drugs Regulation 
(2001).
1.7 This report is based on a review of the literature, including journal articles, 
books and other literature. The ACMD also considered oral and written 
evidence (Annexes C and D respectively) submitted by organisations and 
individuals with particular expertise and special interest in MDMA. 
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2. introduction
2.1 MDMA is a ring-substituted phenylethylamine, a chemical 
derivative of amphetamine. Other related compounds include 
MDEA (3,4-methylenedioxyethylamphetamine) and MDA 
(3,4-methylenedioxyamphetamine), and together these are colloquially 
known as ‘ecstasy’ (often abbreviated to E, X or XTC) although there is 
a range of synonyms that are used. For the purposes of this review, we 
focus on MDMA as currently this is by far the most commonly seized of 
these drugs (Forensic Science Service, 2008a and b, see paragraph 2.5).
2.2 Safrole is the primary precursor for the illicit manufacture of MDMA and is 
a natural product found in sassafras oil (Forensic Science Service, 2008a; 
Dal Cason, 1990). Safrole and a number of other MDMA precursors are 
subject to controls under European Union (EU) regulations. There are 
several methods by which MDMA may be illicitly manufactured, mainly via 
the precursor 3,4-methylenedioxyphenyl-2-propanone (3,4-MDP2P), which 
is prepared from safrole. There are very limited licit requirements for 
3,4-MDP2P and therefore the vast majority of this precursor is obtained by 
illicit manufacture rather than diversion from legitimate sources. 
2.3 In the late 1980s, ‘ecstasy’ was associated with the rave culture. 
However, it then became more widely available in many dance clubs and 
other venues during the 1990s. Data from the British Crime Survey (BCS) 
indicate that use since 1996 has remained relatively stable (British Crime 
Survey, 2008).
2.4 Use of ecstasy is broadly considered ‘recreational’ by the majority of 
users, rather than a drug of daily or dependent use (Measham et al., 
2001; Measham, 2004). A large proportion of individuals who use MDMA 
have previously, or are concurrently (often in the same night), using other 
drugs, particularly alcohol, nicotine/tobacco, cannabis or amphetamine 
(Gross et al., 2002; Riley et al., 2001). There are, therefore, substantial 
problems in attributing field observations of any purported ‘effect’ solely 
to ‘ecstasy’. 
2.5 Data from the Forensic Science Service show that 99% of all police 
seizures of ‘ecstasy’ analysed contain MDMA (Forensic Science Service, 
2008a). Similarly, Dutch data (Drugs Information and Monitoring System 
project) found that since 2000 over 95% of all samples of ‘ecstasy’ 
contained MDMA (R Niesink, pers. comm.).
2.6 MDMA has a distinct pharmacology that differs from that of 
amphetamines and other stimulants (e.g. cocaine) in that it produces a 
sense of warmth and empathy with others, which is why it was considered, 
in the 1950s, to assist in psychotherapy (reviewed in Greer and Tolbert, 
1990; Holland, 2001; Pentney, 2001). 
2.7 Like other stimulants, MDMA produces an increase in drive and energy 
which encourages and allows users to dance for long periods. The 
empathy-producing action has led some to call MDMA an ‘empathogen’ 
or ‘entactogen’. MDMA’s empathogenic properties are thought to be 
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due to the release of serotonin2 (5-hydroxytryptamine (5HT)) in the 
brain, of which MDMA causes the release to a much greater extent than 
other psychostimulants (e.g. cocaine or amphetamine). The ‘energy-
increasing’ effects are thought to reflect brain dopamine3 release as this 
is the main action of other psychostimulants; these dopamine-releasing 
effects are more prominent at higher doses. However, in general, other 
psychostimulants give rise to a considerably greater release of dopamine, 
which probably explains why they are more likely than ‘ecstasy’ to cause 
dependence and paranoia (see paragraph 5.3).
2.8 Tolerance to some of the psychological actions of MDMA are reported in 
some human users of high doses of the drug (Parrott, 2005), which can 
lead to users taking more tablets to get the desired effect. Rats exposed 
to high doses of MDMA exhibit a temporary tolerance to the serotonin-
releasing and behavioural stimulant effects of subsequent doses of 
MDMA (Baumann et al., 2008; Brennan and Schenk, 2006); this may 
represent an animal model for the human tolerance. 
2.9 Most MDMA is currently sold as tablets, the rest as a white or off-white 
powder or very occasionally as crystals (Forensic Science Service, 
2008a). Tablets are often prepared to a high standard using the same 
technology as for prescription medications. Toxic constituents as by-
products of production or through contamination are rare, but tablets 
may have other substances added, possibly to alter their effects (see 
paragraph 2.11).
2.10 Based on current evidence, the ‘ecstasy’ consumed in the UK is produced 
almost exclusively in northern Europe (Association of Chief Police Officers, 
2008; Serious Organised Crime Agency, 2008). Home-based laboratories 
are rare but have been uncovered by police operations as have tableting 
facilities. The chemicals used in MDMA synthesis, though less dangerous 
than those used to synthesise methylamphetamine, can still present 
hazards (such as fires) to the manufacturer and local inhabitants.
2.11 The constituents of tablets sold as ‘ecstasy’ have changed over time. 
In past years, ‘ecstasy’ tablets may have had singularly, or in combination, 
MDMA, MDEA or MDA as the major psychoactive constituents. In more 
recent years, the majority of seized tablets sold as ‘ecstasy’ contain 
MDMA as the primary psychoactive component. However, recent seizures 
of MDMA tablets have also been found to contain other psychoactive 
ingredients including ketamine and benzylpiperazine. For example, around 
9% of tablets seized between July 2007 and June 2008 contained a 
piperazine-type drug (Forensic Science Service, 2008b). In addition, there 
are more recent reports of other stimulants being added to alter the 
psychoactive properties of the MDMA. An example is some Canadian 
seizures where methylamphetamine was present (Forensic Science 
Service, 2008a). This will give users a greater stimulant effect and may be 
included to induce MDMA users onto the more addictive drug. 
2 Serotonin is a neurotransmitter that plays an important role in the modulation of mood, anger, aggression, 
body temperature, sleep, sexuality and appetite (see Glossary).
3 Dopamine is a neurotransmitter that is involved in the regulation of motor function, energy and drive, 
appetite, drug-liking and drug dependence and psychosis (see Glossary).
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2.12 The average content of MDMA in tablets has reduced over the past 
decade from around 100mg per tablet to about 40mg; this may go some 
way to explain the increase in the average number of tablets used per 
user over this period. However, seizures of tablets have shown that the 
MDMA content of a given tablet can vary considerably (Forensic Science 
Service, 2008a and b). 
2.13 The price of ‘ecstasy’ tablets has fallen over recent years and currently 
tablets can cost as little as £2.30, most commonly sold in batches of 
3–5 for £10 (DrugScope, 2006; 2007; 2008). MDMA powder or crystal 
costs about £35–40 per gram and is swallowed, sometimes by dabbing 
a moistened finger into the packet containing the powder, or less often 
wrapped in a piece of cigarette paper and swallowed (F Measham pers. 
comm.). Despite the considerably higher price of MDMA powder over 
tablets, the higher price is seen by some as an indicator of higher quality 
as well as having associations with higher kudos due to its greater cost 
(Measham and Moore, 2009). It is not yet clear from research the extent 
to which users are switching from tablets to powder or adding powder to 
their drug repertoires. MDMA powder is not usually insufflated (snorted) 
as it causes sneezing, pain and nosebleeds. MDMA cannot be smoked 
and is very rarely injected intravenously.
2.14 MDMA was originally used in the USA as an agent to assist in 
psychotherapy (Holland, 2001; Pentney, 2001); this use ceased once it 
became illegal in the USA. In the UK, MDMA was placed in Schedule 1 of 
the Misuse of Drugs Regulations 1975 (and as subsequently amended) 
on the grounds it had no recognised medicinal use.4 MDMA has also 
been used by some people with severe Parkinson’s disease to reduce 
disabling tremor (Concar, 2002). Subsequent research in a mouse model 
of this disease has shown MDMA to be particularly effective in reducing 
symptoms (Sotnikova et al., 2005).
4 The ACMD makes recommendations for both classification (Misuse of Drugs Act 1971) and scheduling 
(Misuse of Drugs Regulations 2001). Medicinal use is covered as appropriate in the scheduling. However, 
the Medicines Act 1968 (under the auspices of the Medicines and Healthcare products Regulatory Agency 
(MHRA)) will cover the medical use of any given drug.
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3. epidemiology of MdMA use, seizures and enforcement
3.1 MDMA is an illegal drug and so data have been obtained from formal 
surveys (such as the BCS) and less formal surveys such as internet-based 
questionnaires and analysis of samples handed in at night clubs and 
dance venues. 
3.2 It has been estimated by the Association of Chief Police Officers (ACPO) 
that between 2.5 and 5 million MDMA tablets are taken every month in 
the UK (Association of Chief Police Officers, 2008). In 2003/04, it was 
also estimated that nearly 60 million ‘ecstasy’ tablets (95% confidence 
interval: 32.7 to 86.3 million) were consumed annually (Home Office, 
2006a), which is consistent with the ACPO estimates. It is uncertain, 
however, whether these estimates have changed over time. Information on 
average consumption by individual users is unavailable to test fully how 
these estimates relate to the number of ‘ecstasy’ users (see paragraph 
3.3). It is likely also that use increases during the summer music festival 
season and during holidays at resorts where clubbing is popular. It is of 
concern that many young people from the UK are introduced to MDMA use 
while abroad on holiday. 
3.3 The BCS (England and Wales) shows that the level of ‘ecstasy’ use has 
remained fairly stable over time with few statistically significant changes 
from one year to the next. The BCS estimates that, in 1996, 1.7% of 16 
to 59-year-olds had used ‘ecstasy’ in the last year. Estimated use peaked 
in 2002/03 with a reported 2.2% of 16 to 59-year-olds having used 
‘ecstasy’, this figure falling to 1.8% in 2006/07 (Home Office, 2008). 
3.4 The 2006/07 BCS estimates that 1.8% of 16 to 59-year-olds had used 
‘ecstasy’ in the last year (Home Office, 2007). In the same survey, among 
adults aged 16–24, 4.8% reported having taken ‘ecstasy’ in the last 
year. An earlier survey – the Offending, Crime and Justice Survey (OCJS) 
conducted in 2003 reported a larger proportion of the population using 
‘ecstasy’ than the BCS. Thus, in 2003 the weighted survey estimates 
were approximately 3% for the OCJS and 2% for the BCS in the last year 
(Home Office, 2006a). 
3.5 Data from the 2006 Scottish Crime and Victimisation Survey and the 
2006/07 Northern Ireland Crime Survey show that 3.2% and 0.9% of  
16 to 59-year-olds surveyed, respectively, had taken ‘ecstasy’ in the last 
year (Scottish Government Social Research, 2007; Northern Ireland Office 
Statistics and Research Branch, 2007).
3.6 Use data for 16 to 24-year-olds from the BCS for England and Wales are 
shown in Table 1 (Home Office, 2007). These are likely to be minimum 
estimates as they do not take account of the under-reporting of population 
surveys such as the BCS. Use in older age groups is lower, though not 
unknown (Anonymous, 2001). Cocaine may be taking over from ‘ecstasy’ 
as the preferred drug of young clubbers, as judged by the higher use of 
this Class A stimulant (Table 1) and increasing medical problems (see 
Section 4).
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table 1. reported drug use by 16 to 24-year-olds, data from the British 
crime survey 2006/07 (home office, 2007)
Drug Used at all last year 
(estimated)
Frequent use i.e. more 
than once a month 
(estimated)
Ecstasy 272,000 (4.8%) 42,000 (0.7%)
Amphetamines 207,000 (3.5%) 25,000 (0.4%)
Cocaine powder 373,000 (6.0%) 95,000 (1.7%)
3.7 Among 11 to 15-year-olds, data for England from 2007 show that 1.8% 
report ever having used ‘ecstasy’ (the percentage figure for use in the 
last year increases with age) (National Centre for Social Research, 
2008). ‘Ecstasy’ use within the 11 to 15-year-old age group in England 
has remained at similar levels since 2001 (National Centre for Social 
Research, 2008). Data from Scotland (Scottish Schools Adolescent 
Lifestyle and Substance Use Survey (SALSUS), 2006) show that the 
percentage of 15-year-olds who reported ever having used ‘ecstasy’ was 
5%. The data from the Scottish survey show the prevalence of reported 
use in the last month was 3% for 15-year-olds and 1% for 13-year-olds 
(SALSUS, 2006). 
3.8 Ongoing surveys of the drug use of club customers from 1997 (Measham, 
Aldridge and Parker, 2001) to 2008 (Measham and Moore, 2009)  
suggest that ‘ecstasy’ use by clubbers has not declined in this 10-year 
period. However, in recent years there appear to be growing trends in  
(a) increased dosage of ‘ecstasy’ by club customers, and (b) the use of a 
growing repertoire of other illicit drugs alongside MDMA in the night-time 
economy, dance club and festival scene (Gross et al., 2002; Measham 
and Moore, 2009). As well as alcohol, cocaine and to a lesser extent 
amphetamines may be co-consumed for their stimulant properties, and 
cannabis, ketamine or benzodiazepines may be used later in the evening 
– usually in private households – reportedly (a) to prolong the socialising 
by attending post-club ‘chill-out’ parties and ‘breakfast clubs’, and (b) 
to reduce the negative effects of the stimulant drug ‘comedown’ phase 
(Moore and Measham, 2008). In some cases, such drug combinations are 
likely to add to health risks, as each are themselves potentially harmful, 
although little research has been done on the consequences of such 
poly-drug use (Measham and Moore, 2009).
3.9 As with all drugs, differing policing priorities and targets do not allow 
relative comparison of seizures of drugs in the same class. However, we 
were informed that ‘ecstasy’ possession has a lower priority than some 
other Class A drugs, specifically heroin and cocaine. Data from 2004 
show that ‘ecstasy-type’ possession offences attracted a greater number 
of cautions (37%) than those for possession of other Class A drugs  
(crack cocaine (15%) or heroin (17%)) though not cocaine powder (37%) 
(Home Office, 2005a).5 Estimates comparing consumption and seizure 
rates from 2003 suggest that less than 10% of ‘ecstasy’ tablets are 
seized, compared with nearly 25% of cannabis and 12% of heroin (Home 
Office, 2006a). However, more recent data from the Home Office indicate 
that seizures of ‘ecstasy’ have increased by 22% since 2005 (Home 
Office, 2008).
5 The greater number of cautions may suggest that ‘ecstasy’ is dealt with more leniently, i.e. cautions are 
given rather than charges brought. 
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3.10 Sentencing data show that the percentage of persons receiving an 
immediate prison sentence for either MDMA supply, intent to supply or 
possession offences is less than those for other Class A drugs (Table 2) 
(Sentencing Guidelines Council, 2007). The data suggest that the courts 
treat offences concerning MDMA more leniently than those of other Class 
A drugs. 
table 2. Percentage of persons sentenced to immediate custody for 
offences related to selected drugs (2007) 
Supply Intent to supply Possession
MDMA 52% (70)6 56% (273) 5%   (68)
Cocaine 67% (344) 73% (814) 4%  (206)
Heroin 72% (809) 80% (835) 9%  (413)
Crack cocaine 81% (197) 79% (248) 9%  (104)
Other Class A drugs 93% (442) 69% (193) 10%  (97)
6 (n) number of persons.
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4. Physical harms 
4.1 MDMA has undoubted harms, causing direct toxicity especially when taken 
in high doses. However, many of the other physical harms of MDMA are 
associated with behaviours in which the users subsequently engage, such 
as energetic dancing for long periods.
4.2 Published literature provides a heterogeneous picture, with case reports 
detailing acute complications including death occurring after limited 
exposure (including consumption of a single tablet) (Rogers et al., 2009). 
Presentations to accident and emergency departments after taking MDMA 
are usually associated with poly-substance use (80% with alcohol, 24% 
cocaine and 21% ketamine) (Dargan, 2008).
4.3 Admission data from Newcastle (Dargan, 2008) show that the number of 
admissions due to MDMA between 2000 and 2007 varies between 22 and 
35 per year. This is compared with around 15 per year for amphetamines 
and, following a recent increase, over 30 per year for cocaine. Data from 
presentations to St Thomas’ Hospital, London (2005 to 2008) show that, 
for those agents classed as recreational drugs, MDMA was the third most 
common drug behind cocaine and GHB, being involved in a total of 382 
presentations (Dargan, 2008). However, of these MDMA presentations, 
only 52 were as sole drug; 85% involved co-ingestants, of which alcohol, 
GHB and ketamine were the most common.
4.4 The total number of admissions to hospital due to MDMA (alone or in 
combination) is not known. But, if the data provided by St Thomas’ and 
Newcastle hospitals are considered indicative, it is likely to be of the 
order of several thousand per year. By way of comparison, there were 
over 57,000 recorded hospital admissions in 2006/07 with a primary 
diagnosis of alcohol poisoning and 846 with a primary diagnosis of 
cannabis poisoning (Department of Health/National Treatment Agency 
for Substance Misuse, 2008). Estimates for all hospital admissions to 
which alcohol contributes are over 800,000 per year with over 200,000 
admissions with alcohol-specific conditions. 
4.5 Data obtained from the National Poisons Information Service (NPIS) 
show that among Class A drugs MDMA, historically, has been the most 
common drug of misuse where information has been accessed (National 
Poisons Information Service, 2008). However, the proportion of telephone 
enquiries related to MDMA acute toxicity fell sharply between 2004/05 
and 2006/07. In contrast, the proportion of those enquiries relating 
to cocaine has increased over the same period and is currently a more 
common drug for enquiry than MDMA (National Poisons Information 
Service, 2008). The NPIS data, however, are limited in providing any 
indication of the true incidence of toxicity cases. 
4.6 MDMA overdose has a profile of toxicity similar to, but with somewhat less 
severe outcomes than that seen with amphetamines and cocaine (Dargan, 
2008). Cardiovascular effects (elevated blood pressure and heart rate) 
are prominent and consistent with the amphetamine-like nature of MDMA; 
epileptic seizures are sometimes seen. Cocaine has a similar toxicity 
profile, but has a higher rate of cardiac problems associated, especially 
myocardial infarction, particularly when taken with alcohol (Devlin and 
Henry, 2008). On rare occasions, use of amphetamines, cocaine and 
MDMA can lead to intracerebral and subarachnoid haemorrhage (Gledhill 
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et al., 1993; McEvoy et al., 2000) and it would appear that, in the 
majority of reported cases, the haemorrhage appeared to be related to an 
underlying vascular malformation.
4.7 MDMA is often taken in night/dance clubs and settings where the 
temperature may already be high and the individual is engaged in prolonged 
dancing. These factors, coupled with MDMA use, can be dangerous, 
especially if associated with dehydration – sometimes leading to exertional 
hyperpyrexia/hyperthermia (raised body temperature). This was the 
explanation for some of the first MDMA fatalities which occurred in dance 
clubs when users had danced for prolonged periods in high temperatures 
while drinking very little water. In 1996, the ACMD acted on these incidents 
and issued advice to Ministers and suggested guidance to users to ensure 
adequate hydration when dancing for long periods (Advisory Council on the 
Misuse of Drugs, 1996). This was coupled with guidance to local authorities 
and club owners to provide free water and ‘chill-out’ rooms, to reduce such 
incidents. New safe clubbing guidelines – Safer Nightlife – have recently 
been issued by the London Drug Policy Forum (2008).
4.8 Water intoxication (with secondary low blood sodium levels – 
hyponatraemia) is a condition also associated with the use of MDMA. 
This can be as a result of excessive water intake, in an attempt to prevent 
dehydration after taking MDMA. In some people, MDMA may cause 
excessive secretion of antidiuretic hormone, which makes the kidneys 
retain water, so aggravating the consequences of excessive water intake 
(Devlin and Henry, 2008). 
4.9 Data presented to the ACMD identified nine published case reports of 
fatalities due to hyponatraemia between 1997 and 2002 and one in 
2006 (Rogers et al., 2009). Twenty-four case series or case reports 
involving non-fatal hyponatraemia were also identified. All fatal cases 
were in women aged between 16 and 21. The propensity for women to be 
disproportionately affected is probably due to the lower ratio of body water 
to body mass in women. 
4.10 Cases of acute liver injury (hepatitis) are occasionally reported. These can 
be secondary to hyperthermia or caused by direct hepatotoxicity from the 
drug; in the latter case, it may re-occur if MDMA is taken again (Devlin and 
Henry, 2008).
4.11 The National Programme on Substance Abuse Deaths (np-SAD) maintains 
the Special Mortality Register (SMR). The dataset is unlikely to be fully 
complete as it records the voluntary submissions of coroners’ reports for 
England and Wales and there are differences in the way coroners, or their 
pathologists, incorporate findings. The General Mortality Register (GMR) is 
a database maintained by the Office for National Statistics (ONS) based on 
information from death certificates and coroners’ reports. Accuracy of the 
dataset relies on the information recorded by the coroner. Full toxicological 
data on all of the drugs detected at post-mortem are not always cited on 
the death certificate, and in some situations it can be difficult to ascribe 
the drug(s) responsible for the death (Hickman et al., 2007).
4.12 Between 1999 and 2001, the data from the GMR show a rise in drug-
related deaths, where ‘ecstasy’ was the sole drug mentioned. Thereafter, 
the number of deaths attributed to ‘ecstasy’ reached a plateau while both 
cocaine- and, to a lesser extent, amphetamine-related deaths continued to 
rise (Figure 1).
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figure 1. general Mortality register drug-related deaths, 1993 to 2006 
(sole drug mentioned): three-year rolling averages for cocaine, MDMA/ 
‘ecstasy’ and amphetamines (excluding MDMA/‘ecstasy’) (rogers  
et al., 2009)
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4.13 Data from the np-SAD for the period 1997 to 2006 recorded that MDMA 
was implicated in a mean of 50 deaths per year and around 10 where it 
was considered the sole drug (Rogers et al., 2009). Data from ONS using 
the GMR in the period 1993 to 2006 record a mean 33 deaths per year 
where MDMA is implicated and 17 where it was considered the sole drug 
(Table 3) (Rogers et al., 2009). The difference between the GMR and 
np-SAD figures will be due to the differences in data reporting and data 
sources used.
table 3. Annual number of deaths recording illicit drugs, general 
Mortality register, 1993 to 2006)7
Mean annual deaths 
(%) – sole drug
Mean annual deaths – 
co-use drug mentions
Heroin and morphine 447 (65.6) 622
Methadone 150 (22.0) 276
Cocaine 31  (4.6) 86
All amphetamines 34  (4.9) 70
  MDMA/‘ecstasy’ 17  (2.5) 337
Cannabis 1  (0.2) 14
GHB 1  (0.2) 2
Source: ONS
4.14 Table 3 shows the number of drug-related deaths for selected causes 
either as the sole drug or as one of the drugs involved. There are fewer 
deaths implicating MDMA than several other Class A drugs (such as 
heroin, methadone and cocaine) and a similar number of deaths due  
to amphetamines.
7 Alcohol was also recorded in an annual average of six co-drug use deaths involving ecstasy.
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4.15 Data from the General Register Office for Scotland (GRO) show that, 
between 1995 and 2007, there was an average of 2.5 deaths a year 
which involved only ‘ecstasy’, or only ‘ecstasy-type’ drugs, or only these 
and alcohol (General Register for Scotland, 2007). 
4.16 Np-SAD data suggest that, for those deaths where MDMA has been 
implicated, the individuals tend to be younger with a greater likelihood of 
being employed. This is in contrast to those deaths where amphetamine 
is implicated. Fatalities where ‘ecstasy’ is implicated also tend to be more 
associated with concurrent alcohol and cocaine use and less with heroin 
and methadone use than those from amphetamines.
4.17 It is particularly difficult to estimate the risk of taking any given MDMA 
dose due to the lack of information on the average level of consumption 
and dose-response relationship between tablet intake and increased risk 
of overdose, as well as uncertainty surrounding the number of ‘ecstasy’ 
users. For example, in 1995/96 a 25-fold range was estimated for 
‘ecstasy’-related death among 15 to 24-year-olds of between one in 2,000 
and one in 50,000 users (Gore, 1999). Equally, if we assume that there 
are 1.2 million adult ‘ecstasy’ users and that approximately 60 million 
tablets are consumed annually (Home Office, 2006a) then the risk of 
death per person and per tablet is: one in 39,000 and one in 1.8 million 
respectively, if all deaths mentioning ‘ecstasy’ are included; and one in 
76,000 and one in 3.5 million respectively, if only those deaths solely 
mentioning ‘ecstasy’ are included. 
4.18 In attempting to quantify the intrinsic fatal toxicity risk of MDMA, as 
measured by the ratio of deaths to availability, we looked at mortality data 
from the ONS for the period 2003 to 2007. Three separate measures 
of an index of fatal toxicity (T1, T2 and T38) were calculated as the total 
number of cases in which the drug was mentioned on death certificates9 
divided by, respectively: (i) the number of users of that drug (T1). The 
number of users (16 to 59-year-olds) was derived from the BCS (Home 
Office, 2004; 2005b; 2006b; 2007) based on the estimated number 
of users in the last year over the same period; (ii) seizures by law 
enforcement agencies (T2). Drug seizure data were taken from Home 
Office (2008); and (iii) estimates of the market size of each drug in 
England and Wales (T3). Market size was derived from Home Office data 
(Home Office, 2006b). The data were then normalised such that, for each 
scale, heroin = 1,000. Values of T1, T2 and T3 are listed in Table 4. For 
each scale, amphetamine, MDMA and cocaine have a broadly similar fatal 
toxicity, which is considerably lower than that of heroin.
table 4. indices of fatal toxicity (t) for the period 2003 to 2007
Drug T1 T2 T3
Heroin/opiates 1,000.0 1,000.0 1000.0
Cocaine 10.9 163.0 92.0
MDMA 4.6 118.0 99.0
Amphetamine 5.0 95.0 106.0
Cannabis < 1.0 2.0 < 1.0
8 We note that there are caveats that must be considered when using all three of these availability metrics.
9 We note that a drug mention on a death certificate does not necessarily indicate causality. 
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4.19 A study of all drug-related deaths in Scotland during the 1990s found that 
every death where MDMA was involved was reported in the newspapers 
(Forsyth, 2001). Deaths due to other drugs were much less likely to be 
reported; for example, only one in 50 were reported for diazepam and 
for amphetamine it was one in three. The skewed reporting of ‘ecstasy’ 
against the landscape of other drug-related harms and deaths is a real 
phenomenon and may heavily impact on public perception.
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5. Acute psychological effects
5.1 MDMA produces a sense of well-being and empathy (indeed, when it was 
originally used in psychotherapy it was called ‘Empathy’). Unlike other 
stimulants (especially crack cocaine and methylamphetamine), MDMA 
does not predispose users to violence and users do not usually present 
problems for policing, even when in large gatherings. MDMA is not a 
hallucinogen like LSD or psilocybin, as users maintain a sense of contact 
with reality, and it is not normally a cause of ‘bad trips’ (Green et al., 
2003), although visual hallucinations may sometimes occur as an adverse 
effect (Davison and Parrott, 1998).
5.2 In common with amphetamine and many of its derivatives, MDMA 
improves arousal, energy, attention and concentration effects – opposite 
to the impairing effects of alcohol (Ramaekers and Kuypers, 2006). 
Although MDMA usually reduces anxiety, in some cases it can lead to 
panic attacks (Whitaker-Azmitia and Aronson, 1989). Irritability in the 
comedown period after MDMA use is widely reported as is a period of 
relatively low mood – the ‘mid-week crash’ (Parrott and Lasky, 1998) (see 
Section 8).
5.3 MDMA differs from other stimulants in that it rarely causes paranoid 
feelings or aggression, both of which are significant problems in 
amphetamine and cocaine users. The reasons for this are not fully 
understood but probably relate to MDMA having a predominant action 
on serotonin pathways in the brain, whereas the other stimulants act 
predominantly through dopamine (Iversen, 2008).
5.4 The effects of MDMA on psychomotor function have been studied during 
driving performance. Studies on MDMA alone have shown that it can 
improve some aspects of driving and impair others (Ramaekers et al., 
2006; Kuypers and Ramaekers, 2008). This contrasts with alcohol which 
impairs on all measures and leads to impulsively impaired judgement. 
There are cases of driving offences associated with MDMA use, but these 
are few in relation to the number of users, and very many fewer than 
those attributable to alcohol (Association of Chief Police Officers, 2008).
5.5 Laboratory studies of acute MDMA administration, using an 80mg dose in 
human volunteers, have revealed that, under the influence of MDMA, there 
is an impairment on word list learning of one to two words out of a total 
of 20 words, an effect similar to that found at the maximum legal blood 
alcohol concentration for driving (80mg/100ml) (Curran, 2008).
5.6 Like amphetamines, MDMA has been found to improve impulse control 
and sustained attention – an effect opposite to that of alcohol (Iversen, 
2008). 
5.7 However, evidence from self-reporting studies demonstrates that memory 
problems have been attributed to ‘ecstasy’ use in mainly ‘moderate’ and 
‘heavy’ users (Parrott, 2002) The degree of self-reported psychobiological 
problems following MDMA use is to an extent determined by the more 
extreme the physical exertion of the user, with more exertion leading to 
more reported problems (Parrott, 2006 et al.). ‘Novice’ or short-term 
users (in terms of lifetime usage) generally remain unimpaired regarding 
memory or other psychobiological problems which are attributed to 
‘ecstasy‘ (Parrott, 2006).  
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6. sub-chronic and chronic psychological effects – does 
MdMA produce long-term harms to the brain? 
6.1 Many approaches to considering whether MDMA use produces long-term 
harms to the brain have been conducted. These include measures of 
serotonin neurochemistry and receptor function, imaging studies on brain 
volume, brain metabolism and neurotransmitter receptors and measures 
of the vulnerability of the brain serotonin system to depletion (Reneman, 
2008). 
6.2 Early rat studies on the pharmacology of MDMA found that as well as 
elevating serotonin it also damaged serotonin neurons (those that release 
serotonin) in the brain (reviewed by Green et al., 2003). Subsequent 
studies in non-human primates produced similar findings (Hatzidimitriou 
et al., 1999), although in mice dopamine neurons were also affected. 
Although the doses used in these studies were considerably higher 
than those typically taken recreationally, these preliminary findings 
raise concerns that MDMA might produce similar nerve cell damage in 
humans.10 However, a recent non-human primate study using dosing 
similar to that seen in humans showed no effect (Fantegrossi et al., 
2004). 
6.3 A systematic review of the observational evidence (Rogers et al., 2009) 
emphasises that reported results should be considered in the context of 
methodological flaws in studies. These authors note that consistency may 
also be reduced by publication bias, selective reporting of outcomes and 
interdependence of some outcome measures. Importantly, within-study 
imbalances in the use of other drugs and alcohol could explain some of 
the effects seen, confounding being most consistently seen with alcohol 
(Rogers et al., 2009). 
6.4 Statistically significant alterations in some brain-imaging measures have 
been reported. Their magnitude is generally less than comparable findings 
in alcohol, cocaine and methylamphetamine misusers and the clinical 
relevance of these findings is unclear. 
6.5 As some animal studies have found that high doses of MDMA can induce 
long-term changes in serotonin nerves in the brain (Green et al., 2003), 
the largest body of imaging research has focused on trying to determine 
whether similar changes occur in humans. Although humans use relatively 
much lower dose levels than those used in the animal experiments, it is 
possible that the human brain might be more susceptible to damage.
6.6 It is theoretically possible to measure damage to serotonin nerves in  
living human brain using neuro-imaging with radioactive tracers that  
bind to the serotonin reuptake sites; a reduction in tracer binding is  
therefore evidence for a reduced number of serotonin nerve terminals  
i.e. consistent with damage to the serotonin nerves as seen in non-human 
primates (Hatzidimitriou et al., 1999). Such human tracer binding studies 
are difficult as they are subject to a number of potential confounds, 
especially the use of other drugs and the effects of residual MDMA in 
10 Note that the most high-profile study of non-human primates was retracted because it subsequently emerged 
that methylamphetamine not MDMA was used (Ricaurte et al., 2002; 2003). 
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the brain which would tend to reduce tracer binding and so mimic nerve 
terminal damage. Moreover, different tracers with different characteristics 
have been used which complicates comparisons between studies. Overall, 
there is evidence for a reduction of tracer binding in various brain regions 
in users of MDMA which is correlated with dose (McCann et al., 1998; 
Reneman et al., 2001; McCann et al., 2005, Buchert et al., 2003). The 
studies suggest that women might be more affected than men (Buchert 
et al., 2003). Earlier studies found this reduction in tracer binding tended 
to be less or not present in ex-users (McCann et al., 2005; Thomasius  
et al., 2006) and a very recent UK study using the current state-of-the-art 
tracer has found no difference between ex-users and controls (Selvaraj 
et al., in press). Taken together, the serotonin imaging data suggest that 
MDMA use may alter tracer binding to serotonin nerve terminals in the 
short term but that this is not permanent. 
6.7 No evidence for any effect on the dopamine system has been found, 
which distinguishes MDMA from stimulants such as methylamphetamine 
and cocaine (Volkow et al., 2001a and b).
6.8 One study has looked at measures of brain metabolism and found 
changes in the frontal cortex in ‘very heavy’ users who had consumed 
more than 700 tablets (Reneman, 2008). A new prospective magnetic 
resonance imaging (MRI) study in the Netherlands performed several 
different brain MRI measurements over a period of several years, during 
which some of the study group had taken MDMA (Reneman, 2008). The 
authors found that MDMA use caused a significant change in fibre tract 
density in the thalamus, but this was not dose related and the relevance 
of these changes are unknown.
6.9 An extensive systematic assessment of observational data on the 
recreational use of MDMA by Rogers et al. (2009) examined studies that 
compared MDMA users versus poly-drug users and MDMA users versus 
drug-naïve controls with separate analyses for current MDMA users and 
ex-users. The review found that there was a small but consistent negative 
effect of ‘ecstasy’ on cognitive and psychomotor function across a large 
number of controlled observational studies (over 100). The authors 
considered these effects tended to be ‘small’ in magnitude, noting that 
the mean scores of ‘ecstasy’-exposed cohorts were commonly still in the 
‘normal range’. Former ‘ecstasy’ users frequently showed deficits that 
matched or exceeded those seen among current users. The statistically 
significant differences reported were most apparent on memory domains 
and on focused but not sustained attention. Self-rated measures of 
performance gave bigger effects than objective measures, which suggests 
a degree of self-concern in those volunteering for research studies. The 
authors of the report suggest that such measures could bias research 
findings (Rogers et al., 2009).
6.10 There has been one prospective study where a group of young people 
were tested on a range of measures before any had taken MDMA and 
then were re-tested two to three years later (Schilt et al., 2007). A 
significant reduction in the improvement of performance on a verbal 
memory task when repeated two to three years later was found in a 
group that had used MDMA (fewer of the ‘ecstasy’ users improved than 
the controls). However, the absolute level of scores was very high in all 
tests and did not differ between the users and non-users. The Council 
was presented with conflicting interpretations as to the potential clinical 
relevance of this data. No significant changes were seen in the other tests 
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conducted and in some tests the MDMA users ‘improved’ more than the 
non-users (Schilt et al., 2007).
6.11 The literature reviewed by Rogers et al. (2009) suggests that, on average, 
‘ecstasy’-exposed cohorts tend not to exhibit exposure effects that 
take them outside of normal ranges. Because such literature describes 
cohorts, rather than individuals, it is not possible to say whether there are 
individual cases in which clinically relevant deficits are apparent, and none 
of the studies identified in the review (Rogers et al., 2009) concerned 
themselves with defining and reporting the incidence of clinically relevant 
differences. 
6.12 The MDMA findings are rather different from those of studies of 
methylamphetamine and cocaine users where impulse control, planning 
and attentional (rather than memory) processes are affected, often to a 
pronounced and clinically relevant degree (Volkow et al., 2001a and b).
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7. dependence
7.1 Generally speaking, a person is said to be psychologically dependent 
on a substance if they experience problems controlling the amount 
and/or frequency of their use and continue to use in spite of adverse 
consequences. Physical dependence may also occur when a person 
requires a higher dose to get a desired effect (tolerance) or experiences 
withdrawal symptoms (World Health Organization, 1996). Unlike 
amphetamines and cocaine, there appears to be little evidence for long-
term physical dependence on MDMA (Nestler, 2005; Iversen, 2008), but 
some withdrawal effects in the form of low mood appear to be commonly 
experienced (see Section 8).
7.2 Although it is unusual, some users develop a compulsive pattern of MDMA 
use, where there may be some degree of tolerance and dose escalation. 
This compulsive use pattern does not appear to be of the same nature 
as in amphetamines and cocaine. The relative lack of dependence liability 
probably reflects the significantly different pharmacology of MDMA to other 
stimulants; MDMA has more effect on brain serotonin and less effect on 
brain dopamine function. 
7.3 Nevertheless, some regular MDMA users do seek specialist treatment 
for MDMA-related problems and assistance to reduce or stop their 
use. Currently these represent 1% of all treatment seekers to services, 
compared with 3% for amphetamines and 11% for cocaine/crack cocaine 
(see Table 5 taken from the published statistics from the National Drug 
Treatment Monitoring System (England) for 2007/2008).
table 5. Primary drug of misuse by age at triage: 2007/08 (england)
Drug Aged less than 18 
years at triage
Aged 18 years 
or over at triage
All persons
N % N % N % Median 
age at 
triage
Heroin 773 5 122,749 66 123,522 61 31
Methadone 15 <0.5 10,097 5 10,112 5 34
Other opiates 43 <0.5 5,404 3 5,447 3 34
Benzodiazepines 59 <0.5 2,029 1 2,088 1 36
Amphetamines 383 2 5,320 3 5,703 3 32
Cocaine 861 5 11,752 6 12,613 6 27
Crack cocaine 168 1 10,826 6 10,994 5 32
Hallucinogens 58 <0.5 344 <0.5 402 <0.5 24
ecstasy 490 3 569 <0.5 1,059 1 18
Cannabis 12,865 78 13,422 7 26,287 13 18
Solvents 321 2 178 <0.5 499 <0.5 15
Barbiturates <5 <0.5 39 <0.5 39 <0.5 35
Major tranquilisers <5 <0.5 39 <0.5 39 <0.5 36
Antidepressants <5 <0.5 171 <0.5 171 <0.5 37
Other drugs 65 <0.5 1,631 1 1,696 <0.5 41
Poly use; no details 65 <0.5 153 <0.5 218 <0.5 29
Drug-free at triage 273 2 745 <0.5 1,018 1 28
total (clients) 16,450 100 185,460 100 201,907 100
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7.4 The Scottish Drug Misuse Database (SDMD) offers a profile of drug 
misusers based on reports submitted on individuals when they first attend 
a service for assessment of their drug misuse problems (Drug Misuse 
Information Scotland, 2007). The data from the SDMD show that less 
than 1% of the total number seeking treatment for the use of illicit drugs 
reported ‘ecstasy’ use as their main drug of misuse. The equivalent 
percentage of those seeking treatment for the use of heroin was 64%. 
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8. MdMA and mental health effects
8.1 MDMA-associated depressive symptoms appear to typically follow 
weekend use and have been termed the ‘mid-week crash’ (Parrott and 
Lasky, 1998). These feelings are generally mild and quickly resolve, 
although some users have been reported to take selective serotonin 
reuptake inhibitor (SSRI) antidepressants to mitigate the effects (Farre 
et al., 2007).
8.2 A concern has been raised that extensive, chronic MDMA use can lead to 
clinical depression, perhaps through changes in brain serotonin function 
discussed in Section 6. The evidence is currently equivocal – most 
studies do not find significantly increased levels of clinical depression 
in current or ex-MDMA users; however, when combined, the available 
evidence suggests that there is a small but significant exposure effect 
(Rogers et al., 2009). One study has found that scores on depression 
rating scales in MDMA users were somewhat elevated compared with 
non-users and this was most marked in those with a specific genotype 
of the serotonin reuptake site (Roiser et al., 2005). Although, even in the 
most affected group, these ratings did not fall within the range considered 
symptomatic of clinical depression.
8.3 Some people with clinical depression find that MDMA can acutely lift 
their mood, albeit only transiently (B. Sessa, pers. comm.). Although it is 
unlikely that much MDMA use is for such self-medication, the scheduling 
status of MDMA has discouraged systematic clinical research work in this 
area. Recently there have been two clinical trials showing that MDMA can 
accentuate the benefits of psychotherapy in the treatment of chronic post-
traumatic stress disorder (PTSD) (Bouso et al., 2008, Mithoefer et al., 
2008). 
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9. societal harms 
9.1 While MDMA clearly can have a major impact on some users and their 
families, there are few data suggesting negative impacts on society when 
directly compared with the other widely used Class A drugs, namely heroin 
and cocaine. Policing priorities in relation to possession (as discussed in 
Section 3) appear to reflect this. 
9.2 MDMA users are more likely to be in employment than heroin, cocaine 
and amphetamine users (Rogers et al., 2009) and usually fund their 
drug purchases from their own income rather than from acquisitive crime 
(Association of Chief Police Officers, 2008). 
9.3 In contrast to alcohol and stimulants, there are few public order offences 
deriving solely from the use of MDMA (Association of Chief Police Officers, 
2008). 
9.4 ‘Ecstasy’ use has been implicated in only a very small proportion of 
serious sexual assault cases (0.65%) (ACPO, pers comm., 2008). 
Compared to ‘ecstasy’, there are over four times as many recorded 
victims of serious sexual assault under the influence of heroin and nearly 
three times as many under the influence of cocaine. In cases where 
the perpetrators are recorded as being, or are believed to be, under the 
influence of ‘ecstasy’, the figures for ‘ecstasy’ and heroin are similar.
9.5 There is evidence of the involvement of organised crime in the trafficking 
of MDMA both into and within the UK. There is less certainty with regard 
to the relative extent to which organised criminal groups specialise in 
such commodity dealing or whether the trafficking of MDMA is part of 
the multi-commodity nature of organised crime where profit and risk are 
assessed against both the commodity and the market. At a local level, 
supply of MDMA is prominently, though not exclusively, based within the 
night club environment. 
9.6 It is not known what impact, if any, the classification of MDMA as Class 
A has on criminal activity. Downgrading would reduce the maximium 
sentence for production or supply from life to 14 years. However, data 
suggest that downgrading would not require concomitant provision of 
greater leniency by the judiciary, as in 2006 there was not one case of 
possession with intent to supply where the sentence given exceeded 
10 years. Whether separating MDMA from other Class A drugs could 
have health and societal benefits through separating drug markets and 
reducing ‘one-stop-shop’ drug dealers that encourage heroin and crack 
cocaine/cocaine use has been suggested, but is not certain.
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10. discussion
10.1 The original classification of MDMA in 1977 under the Misuse of Drugs 
Act 1971 as a Class A drug was carried out before it had become widely 
used and with limited knowledge of its pharmacology and toxicology. Since 
then use has increased enormously, despite it being a Class A drug. As a 
consequence, there is now much more evidence on which to base future 
policy decisions. 
Physical harms
10.2 Use of MDMA is undoubtedly harmful. High doses may lead to death: by 
direct toxicity, in situations of hyperthermia/dehydration, excessive water 
intake, or for other reasons. However, fatalities are relatively low given its 
widespread use, and are substantially lower than those due to some other 
Class A drugs, particularly heroin and cocaine. Although it is no substitute 
for abstinence, the risks can be minimised by following advice such as 
drinking appropriate amounts of water (see Annex E).
10.3 Some people experience acute medical consequences as a result of 
MDMA use which can lead to hospital admission, sometimes with the 
requirement for intensive care. MDMA poisonings are not currently 
increasing in number and are less frequent than episodes due to cocaine. 
10.4 MDMA appears not to have a high propensity for dependence or 
withdrawal reactions although a number of users seek help through 
treatment services.
10.5 MDMA appears to have little acute or enduring effect on the mental health 
of the average user, and unlike amphetamines and cocaine, it is seldom 
implicated in significant episodes of paranoia. 
10.6 There is presently little evidence of longer-term harms to the brain in 
terms of either its structure or function. However, there is evidence for 
some small decline in a variety of domains, including verbal memory, 
even at low cumulative dose. The magnitude of such deficits appears to 
be small and their clinical relevance is unclear. The evidence shows that 
MDMA has been misused in the UK for 20 years but it should be noted 
that long-term effects of use cannot be ruled out. 
10.7 Overall, the ACMD judges that the physical harms of MDMA more closely 
equate with those of amphetamine than of heroin or cocaine. 
societal harms
10.8 MDMA use seems to have few societal effects in terms of intoxication-
related harms or social disorder. However, the ACMD notes the very small 
proportion of cases where ‘ecstasy’ use has been implicated in sexual 
assault. 
10.9 Disinhibition and impulsive, violent or risky behaviours are not commonly 
seen under the influence of MDMA, unlike with cocaine, amphetamines, 
heroin and alcohol.
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10.10 The major issue for law enforcement is ‘ecstasy’s’ position, alongside 
other Class A drugs, as a commodity favoured by organised criminal 
groups. It is therefore generally associated with a range of secondary 
harms connected with the trafficking of illegal drugs. 
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11. recommendations 
11.1 The ACMD emphasises that a harm minimisation approach to the 
widespread use of MDMA should be continued. In 1996, the ACMD 
provided advice to Ministers that outlined important public health 
messages to be promulgated. The key messages remain the same but 
have been revised in light of current data – these are attached at Annex E. 
11.2 MDMA is used widely as part of the club scene alongside other 
recreational drugs. The ACMD acknowledges the FRANK website and 
associated campaigns; however, there is a need for the ‘media-savvy’ user 
population, in particular, to receive accurate information from a credible 
and reliable source on risk and harm reduction advice. Such advice on 
the dangers of use of MDMA with other drugs (poly-drug abuse) should 
be developed with a special emphasis on guidance for young people in 
reducing harm. Access to the Safer Nightlife guidance for those who work 
within the night-life environment should also be encouraged (London Drug 
Policy Forum, 2008).
 recommendation 1: A harm minimisation approach to the widespread 
use of MDMA should be continued.
 recommendation 2: Access to the Safer Nightlife guidance should be 
encouraged.
11.3 In particular, children and young people should receive adequate 
education on the risks and support to encourage abstinence, but noting 
that support, information and advice should be available if they are users. 
 recommendation 3: Young people should receive adequate education on 
the risks of using MDMA to support and encourage abstinence. 
11.4 Parents/carers, teachers and those working in the criminal justice system 
should be informed about the risks of MDMA how these compare with 
those of other drugs. 
 recommendation 4: Parents/carers, teachers and those working in the 
criminal justice system should be informed about the risks of MDMA and 
how these compare with those of other drugs.
11.5 Poisons databases should be refined to capture whether MDMA has 
been used as powder or tablets. Data on psychoactive adulterants in 
MDMA tablets and powders, especially other Class A drugs, should be 
determined on a more systematic basis.11
 recommendation 5: Better data should be captured regarding the form 
and constituents of seized MDMA.
11  The ACMD acknowledges that the Forensic Science Service already collects some data. 
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classification
11.6 In advising the Government on the classification of a substance, the 
Council is required, under the terms of the Misuse of Drugs Act, to 
consider its harmfulness to individuals and society. There is no legal basis 
for the Council, in advising on classification, to take into account matters 
such as the message that is conveyed to the public, or the consequences 
for policing priorities.
11.7 The Council’s recommendation on classification is ultimately a carefully 
considered collective judgement. This judgement is based upon the 
relative harmfulness of substances within the classification system. 
However, the Council must strongly emphasise that the recommendation 
on classification should not detract from the very real harms of MDMA nor 
the public health messages that should be promulgated. 
11.8  It is the Council’s collective view that the balance of harms of MDMA 
most closely equates to substances in Class B. After consideration of the 
totality of evidence, the majority of Council members did not recognise the 
harmful effects of MDMA as commensurate with those of Class A drugs.  
11.9 The Council’s view is that MDMA should be maintained in Schedule 1 – 
having no recognised medicinal use – of the Misuse of Drugs Regulations 
2001 (see also Recommendation 13).  
 recommendation 6: MDMA should be re-classified as a Class B drug. 
research recommendations
11.10 More and improved knowledge of the effects of MDMA upon brain 
mechanisms, including research utilising brain imaging studies, is 
required. This should include concurrent psychomotor and cognitive 
measures of the effects of MDMA on the brain to explore the possibility 
of MDMA-induced neurotoxicity. Comparative studies with other stimulant 
drugs and replication studies in longitudinal cohorts scanned pre- and 
post-drug use, especially controlling for other drugs, are needed. This 
research would consolidate knowledge on the relative harms of MDMA in 
relation to other drugs and so provide a better evidence base for policy 
decisions in future.
 recommendation 7: Research is required into the effects of MDMA upon 
brain mechanisms.
11.11 Improved data are required on the extent and nature of MDMA use in 
under-16s, and on the evolution of the patterns and profile of MDMA use, 
especially in relation to that of other drugs, particularly in combination. 
This research would help inform education messages and the provision of 
health interventions to this group. 
 recommendation 8: Improved data are required regarding the nature and 
extent of MDMA use in under-16s. 
11.12 Further research regarding MDMA should quantify its relative risks and 
also gather information on public attitudes to MDMA in comparison with 
other drugs.
32
Advisory CounCil on the Misuse of drugs
 recommendation 9: Research should quantify the relative risks of, and 
public attitudes towards, MDMA in comparison with other drugs.
11.13 Information on potential alterations in risk and harms from the use of 
MDMA with other drugs – especially alcohol, cocaine and ketamine – 
should be obtained. 
 recommendation 10: More information should be gathered on the risk 
and harms from concurrent use of MDMA and other substances. 
11.14 More research should be focused on the role of vulnerability factors that 
may make individuals more prone to the harms of MDMA. These should 
include studies of results of polymorphisms of genes coding for enzymes 
such as production of COMT (catechole-O-methyl transferase) and MAO 
(monoamineoxidase) which affect serotonin and dopamine metabolism 
and have been suggested to modulate the effects of MDMA. 
 recommendation 11: More research should be focused on the role of 
vulnerability factors that may make individuals more prone to the harms  
of MDMA.
11.15 The potential value of a national scheme to allow drug testing of 
MDMA tablets/powder for individuals’ personal use, such as the Dutch 
Information and Monitoring System (DIMS), should be explored. The 
scheme would have the potential for reducing harm (by promulgating harm 
reduction advice) and would be an important means of developing better 
monitoring data on drug misuse. 
 recommendation 12: Consideration should be given to developing a 
national scheme for the purpose of testing MDMA with a view to providing 
harm reduction advice and developing monitoring data. 
11.16 It is important that research into the medicinal uses of MDMA is not 
disadvantaged by the legislation (Schedule 1 of the Misuse of Drugs 
Regulations 2001). Government should keep under review any further 
clinical efficacy data that emerge.  
 recommendation 13: Research into the medicinal use of MDMA should 
not be disadvantaged by the legislation and the position of MDMA in 
Schedule 1 of the Misuse of Drugs Regulations 2001.
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Annex e: Public health guidance
The advice below is updated from the ACMD’s previous consideration of ecstasy 
and is directed at three groups of people – MDMA users, parents/carers and 
friends of users – although much of the advice is common to all groups. 
The ACMD strongly suggests that government departments promulgate this advice 
as appropriate. 
users
1. Ecstasy is a potentially dangerous drug so the only risk-free option is not to 
take it. Also, some ecstasy tablets contain other substances which may also 
be harmful.
2. It is more dangerous to take ecstasy if you have previously had epileptic fits  
or mental illness or you have had a previous bad experience with the drug.
3. Ecstasy itself can and does occasionally lead to immediate death through 
one of a number of causes. For example, through sudden cessation of 
the heartbeat, blood clots in blood vessels all over the body followed by 
uncontrolled bleeding, and sudden kidney failure. There have been about  
200 ecstasy-related deaths in the last 10 years. 
4. Ecstasy is often taken in clubs and at dance events. The most serious 
dangers are dehydration (loss of water) and heatstroke, which can be fatal. 
Hot environments combined with constant dancing for long periods of time 
will cause the body temperature to rise even more after taking ecstasy. 
water consumption is not an antidote to ecstasy. However, excessive water 
consumption after taking ecstasy can also lead to medical complications and 
some deaths have occurred from this cause. Hence the advice about water 
consumption we have given below is very important (see paragraph 10). 
Combined with mineral intake, water consumption is an antidote to dehydration 
caused by over-exertion.
5. Ecstasy can sometimes cause epileptic fits, panic attacks and confusion, 
conditions which need to be medically treated. There is some evidence to 
suggest it can, in some people, cause damage to the heart and liver as well. 
6. The more ecstasy you take in a session, the more severe the effects are 
likely to be. The use of other substances at the same time (including alcohol) 
increases the likelihood and severity of immediate problems.
7. It has been suggested that regular use of ecstasy over months or years may 
cause brain damage and make you more prone to mental or depressive illness 
in later life. 
8. You may be offered other drugs which it is claimed will make taking ecstasy 
safer. There is no evidence that taking other drugs at the same time reduces 
the dangers. 
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9. If you take ecstasy you can reduce (but not eliminate) the immediate risks as 
follows:
 (i)  If you are dancing (or are in unusually hot conditions), drink about a pint 
of water over each period of an hour – sipped regularly rather than in one 
go. Salt levels in the body should also be kept up by eating salty snacks, 
or drinking fruit juice, fizzy drinks or sports drinks; water is an antidote to 
dehydration, not to ecstasy.
 (ii) If you are not dancing, drink no more than a small glass of water per hour.
10. If you feel unwell after taking ecstasy or are particularly affected by any of the 
following, you should seek medical help:
 (i)  you are not passing urine normally and regularly despite drinking sensibly 
(see above);
 (ii) you feel sick;
 (iii) you feel light-headed or wobbly;
 (iv) your vision becomes blurred;
 (v) you feel panicky; or
 (vi) you feel depressed.
11. Ecstasy affects judgement and you should not operate machinery, drive a 
vehicle or partake in any safety-critical activity while under its influence. It may 
also affect other decisions you make, for example about sexual activity.
12. For more information you can call FRANK on 0800 77 66 00 or visit the 
website at www.talktofrank.com/.
PArents/cArers
1. Remember, your children may be taking ecstasy without you knowing it.
2. Young people take the drug because it makes them feel energetic, happy, 
sociable and comfortable in the company of others. It is not only taken at 
festivals, clubs and dance events; it is also taken at parties and at home.
3. Ecstasy can sometimes cause epileptic fits, feelings of persecution, panic 
attacks, blurred vision and kidney malfunction. These conditions strike 
individuals unpredictably but treatment is usually effective provided it is 
obtained quickly enough. People who have previously suffered epileptic fits or 
mental illness are at particular risk. In some rare cases the medical effects of 
taking ecstasy can result in death.
4. Ecstasy is often taken in clubs and at dance events. The most serious 
dangers are dehydration (loss of water) and heatstroke, which can be fatal. 
Hot environments combined with constant dancing for long periods of time 
will cause the body temperature to rise even more after taking ecstasy. Water 
consumption is not an antidote to ecstasy. Combined with mineral intake, 
water consumption is an antidote to dehydration caused by over-exertion. 
However, excessive water consumption after taking ecstasy can also lead to 
medical complications and some deaths have occurred from this cause. Hence 
the advice about water consumption we have given below is very important.
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5. If your child takes ecstasy he or she can reduce (but not eliminate) the 
immediate risks as follows:
 (i)  If dancing (or in unusually hot conditions), by drinking about a pint of 
water over each period of an hour – sipped regularly rather than in one 
go. Salt levels in the body should also be kept up by eating salty snacks, 
or drinking fruit juice, fizzy drinks or sports drinks; water is an antidote to 
dehydration, not to ecstasy.
 (ii) If not dancing, by drinking no more than a small glass of water per hour.
6. If your child unexpectedly feels unwell through feeling sick, light-headed or 
wobbly, panicky or depressed, or his/her vision becomes blurred, you should 
seek medical help and consider whether the taking of ecstasy has possibly 
brought the problem on.
7. It has been suggested that regular use of ecstasy over months or years may 
cause brain damage and make users more prone to mental or depressive 
illness in later life. 
8. You should talk to your children about ecstasy and other drugs, including 
alcohol and tobacco. The Department of Health produces material that 
provides advice on how to do this. The material is available from doctors’ 
surgeries, in libraries, from some chemists and through FRANK  
(on 0800 77 66 00 or www.talktofrank.com/) and also from the  
Department of Health, PO Box 410, Wetherby LS23 7LN.
frienDs of users
1. If you know your friend has taken ecstasy that evening/recently, try and 
discourage them from taking any more.
2. Users can lose their common sense and indulge in irrational, repetitive 
behaviour. If you see evidence of this behaviour, calmly try to persuade them  
to stop. Don’t be afraid to seek help from others, including medical help.
3. Ecstasy can sometimes have serious consequences. For example, it can bring 
on epileptic fits, feelings of persecution, panic attacks, blurred vision and 
kidney malfunction. These conditions happen unpredictably but treatment is 
usually effective, provided it is obtained quickly enough. People who have 
previously suffered epileptic fits or mental illness are at particular risk. In rare 
cases it can lead to death.
4. You may be able to help friends reduce (but not eliminate) the immediate risks 
as follows:
 (i)  If they are dancing (or are in unusually hot conditions), encourage them to 
drink about a pint of water over each period of an hour – sipped regularly 
rather than in one go. Salt levels in the blood should be kept up by 
encouraging them to eat salty snacks, or to drink fruit juice, fizzy drinks or 
sports drinks; water is an antidote to dehydration, not to ecstasy.
 (ii)  If they are not dancing, encourage them to drink no more than a small 
glass of water per hour.
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5. When dancing in hot conditions the most serious dangers are dehydration 
(loss of water) and heatstroke, which can be fatal. This is because if someone 
dances constantly for hours and hours, their body temperature will rise even 
more after taking ecstasy. However, water is not an antidote to ecstasy, but 
combined with mineral intake (e.g. salty snacks, fruit juice or sports drink) it is 
an antidote to dehydration caused by over-exertion. However, excessive water 
consumption after taking ecstasy can also lead to medical complications and 
some deaths have occurred. Therefore, the advice about water consumption is 
very important.
6. If your friend notices he or she is not passing urine normally, feels sick or 
otherwise feels unwell, you should seek medical help. You should tell the 
assisting services that, if you believe or know they have taken ecstasy, that 
this has possibly brought the problem on.
7. If you are at a dance event and you see evidence of worrying behaviour by a 
friend: 
 (i) try and ensure that they do not get too hot;
 (ii) take regular breaks;
 (iii) give them drink soft drinks to sip regularly (see 5 above); and
 (iv)  consider getting them away from loud music and strobe lighting because 
these can affect them as well.
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glossary 
5ht: 5Hydroxytryptamine – cf. Serotonin (see definition below).
Adulterants: substances added to illicit powders and tablets; they may be 
pharmacologically active or relatively inert and are usually less expensive than the 
drug itself.
Amphetamines: when used in this report, means amphetamine and 
methylamphetamine unless specified.
coMt: catechole-0-methyl transferase: an enzyme that is involved in the breakdown 
of dopamine.
cutting agents: the term is synonymous with adulterants.
DiMs: Dutch Information and Monitoring System: a scheme developed in the 
Netherlands for appraising and tracing new substances. The network also provides 
information to users.
Dopamine: a neurotransmitter involved in the regulation of motor function, energy 
and drive, appetitive, drug-liking and drug dependence and psychosis.
MAo: monoamine oxidase: an enzyme that is involved in the breakdown of 
dopamine and serotonin.
MDA: 3,4-methylenedioxyamphetamine.
MDeA: 3,4-methylenedioxyethylamphetamine.
serotonin: a neurotransmitter involved in many brain functions including regulation 
of mood and anxiety, eating, sleeping, sexual function and cognition. Also known  
as 5HT.
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